Search Result

Results for "

alpha7 nicotinic receptor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	nAChR (52) 5-HT Receptor (8) Antibiotic (2) Apoptosis (5) Autophagy (2) Bacterial (6) Caspase (1) Cholinesterase (ChE) (1) CXCR (4) Dengue virus (2) Endogenous Metabolite (8) Flavivirus (2) GPR35 (4) HIV (2) HSV (2) iGluR (4) Isotope-Labeled Compounds (5) Mitophagy (2) Parasite (2) SARS-CoV (2)
By Research Areas:	Cancer (8) Cardiovascular Disease (1) Endocrinology (4) Infection (5) Inflammation/Immunology (10) Neurological Disease (52)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Antibodies

Targets Recommended: nAChR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B1337

Choline chloride 2 Publications Verification	nAChR Endogenous Metabolite	Cancer
Choline chloride is an essential nutrient that activates **alpha7 nicotinic receptors** and has analgesic and anti-inflammatory activity. Glycerophosphoinositol choline can affect diseases such as liver disease, atherosclerosis and neurological disorders .

HY-12149

A-867744	nAChR	Neurological Disease
A-867744 is a highly potent and selective type II positive allosteric modulator (PAM) of the alpha7 nicotinic acetylcholine receptors (nAChR) with an EC₅₀ of 1.0 μM .

HY-148325

*α7 Nicotinic* receptor agonist-1**	nAChR	Neurological Disease
α7 Nicotinic receptor agonist-1 (Preparation 5) is an α7 nAChR agonist. α7 Nicotinic receptor agonist-1 can be used in studies of psychiatric disorders (such as schizophrenia, manic or hypomanic depression and anxiety disorders) and intellectual disorders (such as alzheimer's disease, learning deficits, cognitive deficits, attention deficits, memory loss, lewy body dementia and attention deficit hyperactivity disorder) .

HY-19490

VQW-765 AQW-051	nAChR	Neurological Disease
VQW-765 (AQW-051) is a selective and orally active alpha-7 nicotinic acetylcholine receptor (α7-nAChR) agonist with a pK_D value of 7.56 to recombinantly expressed human α7-nAChR. VQW-765 shows anxiolytic-like effect in vivo. VQW-765 can be used for the research of anxiety disorder and acute performance anxiety .

HY-14564A

GTS-21 dihydrochloride 5+ Cited Publications DMXB-A; DMBX-anabaseine	nAChR 5-HT Receptor	Inflammation/Immunology
GTS-21 dihydrochloride is a selective alpha7 nicotinic acetylcholine receptor *(α7-nAChR)* agonist with anti‑inflammatory and cognition‑enhancing activities. GTS-21 dihydrochloride is also a α4β2 (K_i=20 nM for humanα4β2) and 5-HT3A receptor (IC₅₀=3.1 μM) antagonist .

HY-B1337B

Glycerophosphoinositol choline	nAChR Endogenous Metabolite	Cardiovascular Disease Inflammation/Immunology Cancer
Glycerophosphoinositol choline is an essential nutrient that activates **alpha7 nicotinic receptors** and has analgesic and anti-inflammatory activity. Glycerophosphoinositol choline can affect diseases such as liver disease, atherosclerosis and neurological disorders .

HY-B1337R

Choline chloride (Standard)	nAChR Endogenous Metabolite	Cancer
Choline (chloride) (Standard) is the analytical standard of Choline (chloride). This product is intended for research and analytical applications. Choline chloride is an essential nutrient that activates alpha7 nicotinic receptors and has analgesic and anti-inflammatory activity. Glycerophosphoinositol choline can affect diseases such as liver disease, atherosclerosis and neurological disorders .

HY-107666

PHA 568487	nAChR	Neurological Disease Inflammation/Immunology
PHA 568487 a selective agonist of alpha-7 nicotinic acetylcholine receptor (α-7 nAchR) .PHA 568487 reduces neuroinflammation and oxidative stress . PHA-568487 has rapid brain penetration .

HY-B1337S5

Choline-13C2 chloride	nAChR Endogenous Metabolite	Cancer
Choline- ¹³C₂ (chloride) is the ¹³C labeled Choline chloride[1]. Choline chloride is an essential nutrient that activates alpha7 nicotinic receptors and has analgesic and anti-inflammatory activity. Glycerophosphoinositol choline can affect diseases such as liver disease, atherosclerosis and neurological disorders[2][3].

HY-14564

GTS-21	nAChR 5-HT Receptor	Inflammation/Immunology
GTS-21 dihydrochloride is a selective alpha7 nicotinic acetylcholine receptor *(α7-nAChR)* agonist with anti‑inflammatory and cognition‑enhancing activities. GTS-21 dihydrochloride is also a α4β2 (K_i=20 nM for humanα4β2) and 5-HT3A receptor (IC₅₀=3.1 μM) antagonist. GTS-21 can be used in age-associated memory impairment (AAMI) and Alzheimer's disease research .

HY-111051

JN403	nAChR	Neurological Disease
JN403 is an orally active and selective α7 nicotinic acetylcholine receptor agonist. JN403 can be used in the study of central nervous system disorders .

HY-107668A

TC-1698	nAChR	Neurological Disease
TC-1698 is a selective α7 **nicotinic acetylcholine receptors agonist with EC₅₀** value of 0.16 μM and 0.46 μM for monkey α7 nicotinic receptor and human α7 nicotinic receptor, respectively. TC-1698 improves memory and has neuroprotective effects. TC-1698 can be used for Alzheimer's disease research .

HY-107668

TC-1698 dihydrochloride	nAChR	Neurological Disease
TC-1698 dihydrochloride is a selective α7 **nicotinic acetylcholine receptors agonist with EC₅₀** value of 0.16 μM and 0.46 μM for monkey α7 nicotinic receptor and human α7 nicotinic receptor, respectively. TC-1698 dihydrochloride improves memory and has neuroprotective effects. TC-1698 dihydrochloride can be used for Alzheimer's disease research .

HY-B0072

Tropisetron 3 Publications Verification SDZ-ICS-930 free base	5-HT Receptor nAChR	Neurological Disease Cancer
Tropisetron (SDZ-ICS-930 free base) is a selective 5-HT3 receptor antagonist (IC₅₀: 70.1 nM) and *α7-nicotinic* receptor agonist** .

HY-N2332A

Methyllycaconitine citrate Maximum Cited Publications 25 Publications Verification MLA	nAChR	Neurological Disease
Methyllycaconitine citrate is a specific antagonist of α7 neuronal nicotinic acetylcholine receptor (α7nAChR) with blood-brain barrier permeability.

HY-129674

PHA 568487 free base	nAChR	Neurological Disease
PHA 568487 free base is a selective alpha 7 nicotinic acetylcholine receptor (α-7 nAchR) agonist. PHA 568487 free base reduces neuroinflammation .

HY-146404

T761-0184	nAChR	Neurological Disease
T761-0184 is a potent *α7 nicotinic* receptor (nAChR)** antagonist .

HY-13225D

Rivanicline fumarate RJR-2403 fumarate; (E)-Metanicotine fumarate	nAChR	Neurological Disease
Rivanicline fumarate is a neuronal nicotinic receptor (neuronal nicotinic receptor) agonist that is highly selective for the α4β2 subtype,K_i is 26 nM, which is more than 1000 times more inhibitory than α7 receptor .

HY-15430A

Encenicline hydrochloride 5 Publications Verification EVP-6124 hydrochloride	nAChR	Neurological Disease
Encenicline hydrochloride (EVP-6124 hydrochloride) is a novel partial agonist of α7 neuronal nicotinic acetylcholine receptors (nAChRs).

HY-15430

Encenicline EVP-6124	nAChR	Neurological Disease
Encenicline (EVP-6124) is a novel partial agonist of α7 neuronal nicotinic acetylcholine receptors (nAChRs).

HY-12560D

PNU-282987 S enantiomer free base	nAChR	Others
PNU-282987 S enantiomer free base is the S-enantiomer of PNU-282987 free base. PNU-282987 is an α7 nicotinic acetylcholine receptor (α7 nAChR) agonist.

HY-13225A

Rivanicline RJR-2403; (E)-Metanicotine	nAChR	Neurological Disease
Rivanicline (RJR-2403; (E)-Metanicotine) is a neuronal nicotinic receptor (neuronal nicotinic receptor) agonist that is highly selective for the α4β2 subtype,K_i is 26 nM, which is more than 1000 times more inhibitory than α7 receptor .

HY-120783

Lu AF58801	Others	Neurological Disease
Lu AF58801 is a potent, orally available, brain-penetrant positive allosteric modulator of α7 nicotinic acetylcholine receptors with efficacy in a novel object recognition task in mice. Lu AF58801 was shown to selectively enhance the activity of α7 nicotinic acetylcholine receptors. Lu AF58801 was able to improve cognitive function in mice treated with subchronic fluchlorothiazol (PCP) .

HY-107682

TQS	nAChR	Neurological Disease Inflammation/Immunology
TQS is a α7 nicotinic acetylcholine receptor (nAChR) positive allosteric modulator. TQS can be used for the research of neuroinflammatory pain .

HY-18060

Bradanicline TC-5619	nAChR	Neurological Disease
Bradanicline is a highly selective α7 nicotinic acetylcholine receptor (nAChR) agonist (humanα7 nAChR: EC₅₀=17 nM; K_i= 1.4 nM). Bradanicline is used for the research of cognitive disorders .

HY-P5623B

RVG TFA RVG29 TFA; RDP TFA; Rabies Virus Glycoprotein-29 TFA	Bacterial	Infection
RVG TFA is a peptide derived from Rabies Virus Glycoprotein that binds to the α-7 subunit of nicotinic acetylcholine receptors (AchR) of neuronal cells. RVG enhances delivery of Mycobacterium tuberculosis antigens to antigen-presenting cells .

HY-P5623

RVG RVG29; RDP; Rabies Virus Glycoprotein-29	Bacterial	Infection
RVG (RVG29) is a peptide derived from Rabies Virus Glycoprotein that binds to the α-7 subunit of nicotinic acetylcholine receptors (AchR) of neuronal cells. RVG enhances delivery of Mycobacterium tuberculosis antigens to antigen-presenting cells .

HY-P1264

α-Bungarotoxin 4 Publications Verification	nAChR	Neurological Disease
α-Bungarotoxin is a competitive antagonist at nicotinic acetylcholine receptors (nAChRs). α-Bungarotoxin, a selective α7 receptor blocker, blocks α7 currents with an IC₅₀ of 1.6 nM and has no effects on α3β4 currents at concentrations up to 3 μM .

HY-16748

Nelonicline ABT-126	nAChR	Neurological Disease
Nelonicline (ABT-126) is an orally active and selective α7 nicotinic receptor agonist with high affinity to α7 nAChRs in human brain (K_i=12.3 nM). Nelonicline is used for the research of shizophrenia and Alzheimer's disease .

HY-167922

(R,R,S)-GAT107	Others	Neurological Disease
(R,R,S)-GAT107 is a fully agonistic positive modulator of α7 nicotinic receptors with significant biological activity. Its activity is entirely present in its (+)-isomer 1b, while (-)-isomer 1a does not affect its activity when used together. Studies have shown that (R,R,S)-GAT107 is the most potent ago-PAM for α7 nicotinic receptors currently known and has the potential for further in vivo evaluation .

HY-16748A

Nelonicline citrate ABT-126 citrate	nAChR	Neurological Disease
Nelonicline (ABT-126) citrate is an orally active and selective α7 nicotinic receptor agonist with high affinity to α7 nAChRs in human brain (K_i=12.3 nM). Nelonicline citrate is used for the research of shizophrenia and Alzheimer's disease .

HY-18039

WAY-361789 SEN15924	Cholinesterase (ChE)	Neurological Disease
WAY-361789 (SEN15924) is an orally active agonist for α7 nicotinic acetylcholine receptor (α7 nAChR) with an EC₅₀ of 0.18 μM. WAY-361789 improves the cognitive function, exhibits potential in ameliorating Alzheimer’s Disease and schizophrenia .

HY-18060A

Bradanicline hydrochloride TC-5619 hydrochloride	nAChR	Neurological Disease
Bradanicline hydrochloride (TC-5619 hydrochloride) is the hydrochloride salt form of Bradanicline (HY-18060). Bradanicline hydrochloride is a selective agonist for α7 nicotinic acetylcholine receptor (nAChR), with EC₅₀ of 17 nM for human α7 nAChR and K_i of 1.4 nM. Bradanicline hydrochloride is used for the research of cognitive disorders and schizophrenia .

HY-B0942S

Benzethonium-d7 chloride	Isotope-Labeled Compounds nAChR	Neurological Disease
Benzethonium-d7 chloride is the deuterium labeled Benzethonium chloride. Benzethonium chloride inhibit human recombinant α7 and α4β2 neuronal nicotinic acetylcholine receptors in Xenopus oocytes.

HY-107671

DMAB-anabaseine dihydrochloride	nAChR	Neurological Disease
DMAB-anabaseine dihydrochloride is a selective **nicotinic α7 receptor partial agonist and an α4β2 nAChR** antagonist. DMAB-anabaseine dihydrochloride shows cognition-enhancing effects .

HY-120609

BMS-902483	nAChR	Neurological Disease
BMS-902483 is a quinuclidine-containing spirooxazolidine that is a partial agonist of the α7 nicotinic acetylcholine receptor (nAChR). BMS-902483 improves cognitive ability in preclinical rodent models. .

HY-107512

Kynurenic acid sodium 3 Publications Verification	iGluR Apoptosis Endogenous Metabolite CXCR GPR35	Neurological Disease Inflammation/Immunology Endocrinology
Kynurenic acid sodium, an endogenous tryptophan metabolite, is a broad-spectrum antagonist targeting NMDA, glutamate, α7 nicotinic acetylcholine receptor. Kynurenic acid sodium is also an agonist of GPR35/CXCR8.

HY-100806

Kynurenic acid 3 Publications Verification Quinurenic acid	iGluR Endogenous Metabolite Apoptosis CXCR GPR35	Neurological Disease Inflammation/Immunology Endocrinology
Kynurenic acid, an endogenous tryptophan metabolite, is a broad-spectrum antagonist targeting NMDA, glutamate, α7 nicotinic acetylcholine receptor. Kynurenic acid is also an agonist of GPR35/CXCR8.

HY-108038

ABT-107	nAChR	Neurological Disease
ABT-107 is a selective α7 neuronal nicotinic receptor agonist. ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions .

HY-108057

Facinicline RG3487 free base	nAChR 5-HT Receptor	Neurological Disease
Facinicline (RG3487) is an orally active **nicotinic α7 receptor partial agonist, with a K_i** of 6 nM for α7 human nAChR. Facinicline improves cognition and sensorimotor gating in rodents. Facinicline hydrochloride shows high affinity (antagonist) to 5-HT₃Rs with a K_i value of 1.2 nM .

HY-B0942R

Benzethonium chloride (Standard)	nAChR Bacterial	Neurological Disease
Benzethonium (chloride) (Standard) is the analytical standard of Benzethonium (chloride). This product is intended for research and analytical applications. Benzethonium chloride inhibits nicotinic acetylcholine receptors in human recombinant α7 and α4β2 neurons in Xenopus laevis oocytes.

HY-108057A

Facinicline hydrochloride RG3487 hydrochloride	nAChR 5-HT Receptor	Neurological Disease
Facinicline hydrochloride (RG3487 hydrochloride) is an orally active **nicotinic α7 receptor partial agonist, with a K_i** of 6 nM for α7 human nAChR. Facinicline hydrochloride (RG3487 hydrochloride) improves cognition and sensorimotor gating in rodents. Facinicline hydrochloride (RG3487 hydrochloride) shows high affinity (antagonist) to 5-HT₃Rs with a K_i value of 1.2 nM .

HY-106901A

Asoxime dichloride HI-6	nAChR	Neurological Disease
Asoxime dichloride (HI-6) is an antagonist to *acetylcholine receptors* (AChRs)** including the nicotinic receptor, α7 nAChR. Asoxime dichloride involves in modulating immunity response. Asoxime dichloride (HI-6) can be used as an antigen and improves vaccination efficacy in the nervous system .

HY-133011

nAChR agonist 1	nAChR	Neurological Disease
nAChR agonist 1 is a potent, brain-permeable, and orally efficacious positive allosteric modulator of *α7 nicotinic* acetylcholine receptor (α7 nAChR). nAChR agonist 1 has the EC₅₀** of 0.32 µM in a Ca ²⁺ mobilization assay (PNU-282987-induced, FLIPR based) in human IMR-32 neuroblastoma cells that endogenously express α7 nAChR. nAChR agonist 1 can be develpoped for the treatment of Alzheimer’s disease .

HY-19411

SSR180711 hydrochloride	nAChR	Neurological Disease
SSR180711 hydrochloride is an orally active, selective and reversible *α7 acetylcholine nicotinic* receptor (n-AChRs) partial agonist. SSR180711 hydrochloride can act on rat α7 n-AChR (K_i=22 nM; IC₅₀=30 nM) and human α7 n-AChR (K_i=14 nM; IC₅₀**=18 nM). SSR180711 hydrochloride increases glutamatergic neurotransmission, ACh release and long-term potentiation (LTP) in the hippocampus .

HY-13225

Rivanicline oxalate RJR-2403 oxalate; (E)-Metanicotine oxalate	nAChR	Neurological Disease
Rivanicline oxalate (RJR-2403 oxalate; (E)-Metanicotine oxalate) is a neuronal nicotinic receptor agonist, showing high selectivity for the α4β2 subtype (K_i=26 nM); > 1,000 fold selectivity than α7 receptors(K_i= 3.6 μM).

HY-13225B

Rivanicline hemioxalate 1 Publications Verification RJR-2403 hemioxalate; (E)-Metanicotine hemioxalate	nAChR	Neurological Disease
Rivanicline hemioxalate (RJR-2403 hemioxalate; (E)-Metanicotine hemioxalate) is a neuronal nicotinic receptor agonist, showing high selectivity for the α4β2 subtype (K_i=26 nM); > 1,000 fold selectivity than α7 receptors(K_i= 3.6 μM).

HY-12560A

PNU-282987 5+ Cited Publications	nAChR 5-HT Receptor	Neurological Disease
PNU-282987 is a potent *α7 nicotinic* acetylcholine receptor (nAChR) agonist with an EC₅₀** of 154 nM. PNU-282987 is also a functional antagonist of the 5-HT₃ receptor with an IC₅₀ of 4541 nM. PNU-282987 can be used for the research of central and peripheral nervous systems .

HY-100806S

Kynurenic acid-d5 Quinurenic acid-d₅	Isotope-Labeled Compounds iGluR Endogenous Metabolite Apoptosis CXCR GPR35	Neurological Disease Inflammation/Immunology Endocrinology
Kynurenic acid-d₅ is the deuterium labeled Kynurenic acid. Kynurenic acid, an endogenous tryptophan metabolite, is a broad-spectrum antagonist targeting *NMDA, glutamate, α7 nicotinic* acetylcholine receptor. Kynurenic acid is also an agonist of GPR35/CXCR8[1][2].**

HY-100806R

Kynurenic acid (Standard) 3 Publications Verification Quinurenic acid (Standard)	iGluR Endogenous Metabolite Apoptosis CXCR GPR35	Neurological Disease Inflammation/Immunology Endocrinology
Kynurenic acid (Standard) is the analytical standard of Kynurenic acid. This product is intended for research and analytical applications. Kynurenic acid, an endogenous tryptophan metabolite, is a broad-spectrum antagonist targeting NMDA, glutamate, α7 nicotinic acetylcholine receptor. Kynurenic acid is also an agonist of GPR35/CXCR8.

Cat. No.	Product Name	Target	Research Area

HY-P5623B

RVG TFA RVG29 TFA; RDP TFA; Rabies Virus Glycoprotein-29 TFA	Bacterial	Infection
RVG TFA is a peptide derived from Rabies Virus Glycoprotein that binds to the α-7 subunit of nicotinic acetylcholine receptors (AchR) of neuronal cells. RVG enhances delivery of Mycobacterium tuberculosis antigens to antigen-presenting cells .

HY-P1264

α-Bungarotoxin 4 Publications Verification	nAChR	Neurological Disease
α-Bungarotoxin is a competitive antagonist at nicotinic acetylcholine receptors (nAChRs). α-Bungarotoxin, a selective α7 receptor blocker, blocks α7 currents with an IC₅₀ of 1.6 nM and has no effects on α3β4 currents at concentrations up to 3 μM .

HY-P5623

RVG RVG29; RDP; Rabies Virus Glycoprotein-29	Bacterial	Infection
RVG (RVG29) is a peptide derived from Rabies Virus Glycoprotein that binds to the α-7 subunit of nicotinic acetylcholine receptors (AchR) of neuronal cells. RVG enhances delivery of Mycobacterium tuberculosis antigens to antigen-presenting cells .

HY-P5823

Azemiopsin	nAChR	Neurological Disease
Azemiopsin is a potent nicotinic acetylcholine receptor (nAChR) inhibitor with IC₅₀s of 0.18 μM and 22 μM against T. californica nAChR and human α7 nAChR, respectively. Azemiopsin blocks acetylcholine-induced currents in Xenopus oocytes heterologously expressing human muscle-type nAChR .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B1337

Choline chloride 2 Publications Verification	Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Cancer	nAChR Endogenous Metabolite
Choline chloride is an essential nutrient that activates **alpha7 nicotinic receptors** and has analgesic and anti-inflammatory activity. Glycerophosphoinositol choline can affect diseases such as liver disease, atherosclerosis and neurological disorders .

HY-107512

Kynurenic acid sodium 3 Publications Verification	Structural Classification Alkaloids Classification of Application Fields Source classification Quinoline Alkaloids Endogenous metabolite Inflammation/Immunology Disease Research Fields	iGluR Apoptosis Endogenous Metabolite CXCR GPR35
Kynurenic acid sodium, an endogenous tryptophan metabolite, is a broad-spectrum antagonist targeting NMDA, glutamate, α7 nicotinic acetylcholine receptor. Kynurenic acid sodium is also an agonist of GPR35/CXCR8.

HY-100806

Kynurenic acid 3 Publications Verification Quinurenic acid	Alkaloids Structural Classification Human Gut Microbiota Metabolites Microorganisms Neurological Disease Classification of Application Fields Quinoline Alkaloids Endogenous metabolite Disease Research Fields Endocrinology	iGluR Endogenous Metabolite Apoptosis CXCR GPR35
Kynurenic acid, an endogenous tryptophan metabolite, is a broad-spectrum antagonist targeting NMDA, glutamate, α7 nicotinic acetylcholine receptor. Kynurenic acid is also an agonist of GPR35/CXCR8.

HY-100806R

Kynurenic acid (Standard) 3 Publications Verification Quinurenic acid (Standard)	Structural Classification Alkaloids Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Source classification Quinoline Alkaloids Endogenous metabolite	iGluR Endogenous Metabolite Apoptosis CXCR GPR35
Kynurenic acid (Standard) is the analytical standard of Kynurenic acid. This product is intended for research and analytical applications. Kynurenic acid, an endogenous tryptophan metabolite, is a broad-spectrum antagonist targeting NMDA, glutamate, α7 nicotinic acetylcholine receptor. Kynurenic acid is also an agonist of GPR35/CXCR8.

HY-15310

Ivermectin Maximum Cited Publications 24 Publications Verification MK-933; CD-5024; K-237	Structural Classification Microorganisms Macrolide Antibiotics Classification of Application Fields Antibiotics Source classification Antiviral Anti-parasitic Disease Research Disease Research Fields Cancer	Flavivirus Dengue virus Parasite HIV Mitophagy HSV SARS-CoV Antibiotic Autophagy Bacterial
Ivermectin (MK-933) is a broad-spectrum anti-parasite agent. Ivermectin (MK-933) is a specific inhibitor of Impα/β1-mediated nuclear import and has potent antiviral activity towards both HIV-1 and dengue virus. It is a positive allosteric effector of P2X₄ and the α7 neuronal nicotinic acetylcholine receptor (nAChRs). Ivermectin also inhibits bovine herpesvirus1 (BoHV-1) replication and inhibits BoHV-1 DNA polymerase nuclear import . Ivermectin is a candidate therapeutic against SARS-CoV-2/COVID-19 .

HY-B1337B

Glycerophosphoinositol choline	Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields Cancer	nAChR Endogenous Metabolite
Glycerophosphoinositol choline is an essential nutrient that activates **alpha7 nicotinic receptors** and has analgesic and anti-inflammatory activity. Glycerophosphoinositol choline can affect diseases such as liver disease, atherosclerosis and neurological disorders .

HY-B1337R

Choline chloride (Standard)	Structural Classification Natural Products Source classification Endogenous metabolite	nAChR Endogenous Metabolite
Choline (chloride) (Standard) is the analytical standard of Choline (chloride). This product is intended for research and analytical applications. Choline chloride is an essential nutrient that activates alpha7 nicotinic receptors and has analgesic and anti-inflammatory activity. Glycerophosphoinositol choline can affect diseases such as liver disease, atherosclerosis and neurological disorders .

HY-114791

Lobelanidine	Structural Classification Alkaloids Lobelia tupa L. Other Alkaloids Source classification Campanulaceae Plants	nAChR
Lobelanidine is an antagonist for nicotinic acetylcholine receptor (nAChR), which inhibits α7 nAChR response and α3β2/α3β4 nAChR responses, with IC₅₀ of 2.8 and 8.2 μM .

HY-15310R

Ivermectin (Standard)	Structural Classification Microorganisms Macrolide Antibiotics Antibiotics Source classification Antiviral Anti-parasitic Disease Research	Dengue virus Flavivirus Parasite HIV Mitophagy HSV SARS-CoV Antibiotic Autophagy Bacterial
Ivermectin (Standard) is the analytical standard of Ivermectin. This product is intended for research and analytical applications. Ivermectin (MK-933) is a broad-spectrum anti-parasite agent. Ivermectin (MK-933) is a specific inhibitor of Impα/β1-mediated nuclear import and has potent antiviral activity towards both HIV-1 and dengue virus. It is a positive allosteric effector of P2X₄ and the α7 neuronal nicotinic acetylcholine receptor (nAChRs). Ivermectin also inhibits bovine herpesvirus1 (BoHV-1) replication and inhibits BoHV-1 DNA polymerase nuclear import . Ivermectin is a candidate therapeutic against SARS-CoV-2/COVID-19 .

Cat. No.	Product Name	Chemical Structure

HY-B0942S

Benzethonium-d7 chloride
Benzethonium-d7 chloride is the deuterium labeled Benzethonium chloride. Benzethonium chloride inhibit human recombinant α7 and α4β2 neuronal nicotinic acetylcholine receptors in Xenopus oocytes.

HY-100806S

Kynurenic acid-d5
Kynurenic acid-d₅ is the deuterium labeled Kynurenic acid. Kynurenic acid, an endogenous tryptophan metabolite, is a broad-spectrum antagonist targeting *NMDA, glutamate, α7 nicotinic* acetylcholine receptor. Kynurenic acid is also an agonist of GPR35/CXCR8[1][2].**

HY-106901AS

Asoxime-d4 dichloride
Asoxime-d₄ (dichloride) is the deuterium labeled Asoxime dichloride. Asoxime dichloride (HI-6) is an antagonist to acetylcholine receptors (AChRs) including the nicotinic receptor, α7 nAChR. Asoxime dichloride involves in modulating immunity response. Asoxime dichloride (HI-6) can be used as an antigen and improves vaccination efficacy in the nervous system[1].

HY-B1337S5

Choline-13C2 chloride
Choline- ¹³C₂ (chloride) is the ¹³C labeled Choline chloride[1]. Choline chloride is an essential nutrient that activates alpha7 nicotinic receptors and has analgesic and anti-inflammatory activity. Glycerophosphoinositol choline can affect diseases such as liver disease, atherosclerosis and neurological disorders[2][3].

HY-10019S

Varenicline-d4

Varenicline-d₄ is deuterium labeled Varenicline. Varenicline (CP 526555) is a potent partial agonist for α4β2 nicotinic acetylcholine receptor (nAChR) with an EC50 value of 2.3 μM. Varenicline is a full agonist for α3β4 and α7 nAChRs with EC50 values of 55 μM and 18 μM, respectively[1]. Varenicline is a nicotinic ligand based on the structure of cytisine, has the potential for smoking cessation treatment[2].

HY-10019AS1

Varenicline-d4 hydrochloride

Varenicline-d₄ hydrochloride is a deuterium labeled Varenicline (dihydrochloride) (HY-10019A) . Varenicline (CP 526555) dihydrochloride is a potent partial agonist for α4β2 nicotinic acetylcholine receptor (nAChR) with an EC₅₀ value of 2.3 μM. Varenicline dihydrochloride is a full agonist for α3β4 and α7 nAChRs with EC₅₀ values of 55 μM and 18 μM, respectively . Varenicline dihydrochloride is a nicotinic ligand based on the structure of cytosine, and has the potential for smoking cessation treatment .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P83668

	CHRNA7 Antibody 7nAChR,CHRFAM7A,CHRNA7 (cholinergic receptor; nicotinic; alpha 7; exons 5-10) and FAM7A (family with sequence similarity 7A; exons A-E) fusion; D-10; CHRNA7; CHRNA7-DR1	IHC-P, FC, ELISA	Human

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks